Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Medication Adherence 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Gastrointestinal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colonic Neoplasms 1

Interventions

Imatinib Mesylate 86nilotinib 59fludarabine phosphate 46Cyclophosphamide 45Mycophenolic Acid 37Whole-Body Irradiation 35Dasatinib 32fludarabine 31Tacrolimus 29Cyclosporine 24Busulfan 23Peripheral Blood Stem Cell Transplantation 22Methotrexate 20bosutinib 18Cytarabine 18Granulocyte Colony-Stimulating Factor 16Filgrastim 16Melphalan 14thymoglobulin 13Antilymphocyte Serum 13Stem Cell Transplantation 12sargramostim 11Thiotepa 11Interferon-alpha 10Cord Blood Stem Cell Transplantation 9ponatinib 8asciminib 8Cyclosporins 8Sirolimus 7Radiotherapy 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Pharmaceutical Services × Clear all
NCT03090477 2019-04-05

Impact of a Pharmaceutical Care Model in the Management of Chronic Myeloid Leukemia Patients

UCSI University

Phase NA Completed
129 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Medication Adherence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡